New hope for liver cancer patients with damaged livers?
NCT ID NCT05622071
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tested a drug called tislelizumab in 50 adults with advanced liver cancer and moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors and how safe it was. Participants received tislelizumab alone, and the study measured how many had their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA BY BCLC STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Strasbourg
Strasbourg, France
-
CHU Angers
Angers, France
-
CHU Beaujon
Clichy, France
-
CHU La Croix Rousse
Lyon, France
-
CHU Saint Eloi
Montpellier, France
-
Centre Eugene Marquis
Rennes, France
-
Hôpital Avicenne
Bobigny, France
-
Hôpital Michallon
Grenoble, France
-
Hôpital Saint Joseph
Marseille, France
-
Institut Paoli Calmette
Marseille, France
Conditions
Explore the condition pages connected to this study.